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ABSTRACT 
Background and Aims  
Historical and emerging data implicate fungi in Crohn’s disease (CD) pathogenesis. 
However, a causal link between mycobiota, dysregulated immunity and any impact 
of NOD2 variants remains elusive. This study aims to evaluate associations between 
NOD2 variants and faecal mycobiota in CD patients and non-CD subjects. 
Methods 
Faecal samples were obtained from 34 CD patients (18 NOD2 mutant, 16 NOD2 
wild-type) identified from the UK IBD Genetics Consortium. To avoid confounding 
influence of mucosal inflammation CD patients were in clinical remission and had a 
faecal calprotectin <250 μg/g.  47 non-CD subjects were included as comparator 
groups, including 22 matched household (4 NOD2 mutant) and 25 non-household 
subjects with known NOD2 genotype (14 NOD2 mutant) identified by the NIHR 
BioResource Cambridge. Faecal mycobiota composition was determined using ITS1 
sequencing, and compared to 16S rRNA gene sequences and volatile organic 
compounds.  
Results  
CD was associated with higher numbers of observed fungal OTUs (P=0.033). 
Principal coordinates analysis using Jaccard index (P=0.018) and weighted Bray-
Curtis dissimilarities (P=0.01) showed Candida spp. clustered closer to CD patients 
whereas Cryptococcus spp. clustered closer to non-CD. In CD, we found higher 
relative abundance of Ascomycota (P=0.001) and lower relative abundance 
Basidiomycota (P=0.019) phyla. An inverse relationship was found between bacterial 
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and fungal Shannon diversity in NOD2 wild-type that was independent of CD (r=-
0.349; P=0.029).  
Conclusion  
This study confirms compositional changes in the gut mycobiota in CD and provides 
evidence that fungi may play a role in CD pathogenesis. No NOD2 genotype-specific 
differences were observed in the faecal mycobiota. 
 
Keywords: Crohn’s Disease, NOD2 genotype, gut mycobiota 
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1. INTRODUCTION 
Crohn’s disease (CD) is a chronic relapsing inflammatory disease of the 
gastrointestinal (GI) tract, which affects the quality of life of over 1.5 million 
individuals in North America and Europe.1,2 While inflammation may occur at any 
point along the GI tract, CD commonly affects the terminal ileum and colon,3 and can 
lead to significant tissue damage, often necessitating the introduction of biological 
therapy, and in many patients surgical intervention.4-6 While the aetiology and 
pathogenesis of CD remain unresolved, the likely mechanisms involve complex 
interactions between predisposing genes and environmental exposures, which lead 
to aberrant immune responses against the gut microbiota, resulting in an imbalanced 
microbial community.7-10 
CD patients have altered gut bacterial communities that include imbalances in 
Bacteroidetes, Firmicutes, and Proteobacteria phyla.11-13 The gut microbiota of the 
healthy adult GI tract includes the fungal mycobiota14-16 and a study by Sokol and 
colleagues, which examined the faecal mycobiota in adult CD patients reported 
fungal dysbiosis.17 Furthermore, a number of studies evaluating the faecal mycobiota 
in CD report increased prevalence of Candida spp.,17-19 although the link between 
increased abundance and disease pathogenesis remains obscure.  
The strongest genetic association for CD susceptibility is in the gene encoding the 
nucleotide-binding oligomerisation domain-containing protein 2 (NOD2; also known 
as CARD15).20,21 The 3 most common CD-associated NOD2 mutations; R702W and 
G908R result in amino acid substitutions and L1007fsinsC results in a premature 
stop codon and dysfunctional NOD2. In Caucasians, up to 50% of CD patients carry 
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at least one NOD2 mutation and individuals that carry two mutated NOD2 alleles 
have a 20-40-fold increased risk of developing CD.20,21 
NOD2 is a cytosolic pattern recognition receptor that is highly expressed in dendritic 
cells and macrophages,22 Paneth cells,23,24 and variably expressed in intestinal 
epithelial cells.25 NOD2 is activated by muramyl dipeptide (MDP), a bacterial cell wall 
component26,27 and upregulates expression of cytokines, chemokines, defensins, 
and triggers adaptive immune responses.28 The 3 major CD-associated mutations 
are located within the ligand recognition domain of the NOD2 protein and are 
therefore defective in their ability to sense MDP and trigger autophagy, which impairs 
gut bacterial handling.29,30  
A number of studies have investigated the impact of NOD2-bacterial interactions in 
CD,31-35 including a retrospective study by Frank et al., which found NOD2-specific 
compositional shifts in the intestinal-associated bacterial community.34 Recently and 
in contrast, Kennedy & colleagues evaluated the impact of NOD2 variants on the 
faecal bacterial community in well-phenotyped CD patients compared to matched 
controls and found no NOD2-specific alterations in the bacterial communities.35 
An intriguing study by Wagener and co-workers demonstrated that NOD2 is also 
activated by the fungal wall component chitin and induces interleukin 10 secretion, 
so NOD2-dependent recognition of chitin-particles dampens inflammatory 
responses.36 Currently, it is unknown what impact NOD2 genetic variants may have 
on the gut mycobiota in healthy individuals or patients with CD. 
There were three aims of this study. First, to investigate the faecal mycobiota of CD 
patients in remission and non-CD individuals to determine whether there are unique 
fungal signatures that distinguish between the two groups, and if NOD2 genotype 
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impacts upon the composition of the faecal mycobiota. Second, to compare the 
relative abundance of fungal and bacterial communities to identify potential 
correlations that may be implicated in CD and/or NOD2 genotype. Third, to 
determine whether there are specific correlations between volatile organic 
compounds (VOC) and bacteria or fungi detectable in the faecal contents.  
2. MATERIALS & METHODS 
2.1 Study participants 
This study used clinical data, stool samples, 16S rRNA gene sequences (accessible 
from the European Nucleotide Archive, accession number PRJEB21593) and faecal 
volatile organic compounds (VOC) collected previously for a study to investigate the 
impact of NOD2 genotype on faecal bacterial community profiles in CD and non-CD 
individuals.35 NOD2 mutant CD patients were selected if they carried 2 copies 
(homozygous or compound heterozygotes) of the CD-associated NOD2 mutations 
(R702W [rs2066844], G908R [rs2066845] or L1000fs [rs2066847]). NOD2 mutant 
CD patients were matched for age, gender and geographical location to a wild-type 
NOD2 CD patient. To avoid the confounding influence of inflammation, CD patients 
were confirmed to be in clinical remission as defined by physician assessment and a 
faecal calprote tin <250 μg/g.6 All non-CD subjects had a faecal calprotectin <100 
μg/g.6 Healthy controls were stratified by the same NOD2 genotypes i.e., NOD2 wild-
type and NOD2 mutant (compound heterozygotes, other homozygotes and single 
heterozygotes). Two non-CD comparator groups were recruited for this study.35 
Firstly an environmental control group, where possible a household member (usually 
an unrelated spouse) of CD participants was recruited for stool sample collection and 
saliva for NOD2 genotyping. Secondly, a genetic control group of volunteers of 
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known NOD2 genotype were recruited from the NIHR Cambridge BioResource for 
stool sample collection. All stool samples were frozen within 24 hours of collection. 
Ethical approval was obtained from the North of Scotland Research Ethics 
Committee (reference 12/NS/0050). All study participants provided written consent. 
2.2 ITS1 sequencing 
DNA was extracted from 0.2 g stool samples with the DNeasy PowerLyzer 
PowerSoil kit (QIAGEN, Manchester, UK) and processed according to the 
manufacturers protocol. A DNA extraction kit negative control was processed 
alongside each batch of 23 samples and sequenced. ITS1 sequencing was carried 
out by NU-OMICs (Northumbria University, Newcastle upon Tyne, UK). Briefly, PCR 
amplification of the internal transcribed spacer 1 (ITS1) region of the eukaryotic 
ribosomal cluster was amplified using primers ITS1F 
(CTTGGTCATTTAGAGGAAGTAA) and ITS2 (GCTGCGTTCTTCATCGATGC) using 
a previously described method14 and adapted as below. PCR reactions were made 
up in a total volume of 20 µL using 1x AccuPrime™ Pfx Reaction Mix, 0.5 µM each 
primer, 500 ng bovine serum albumin, 2.5 U AccuPrime™ Pfx DNA Polymerase and 
14.25 µL of template DNA. PCR cycling conditions: initial denaturation at 95 °C for 2 
min, 35 amplifi ation cycles of 95 °C for 30 s, 52 °C for 30 s, 68 °C for 30 s, followed 
by a final extension step of 68 °C for 7 min. PCR products were cleaned and 
normalised using the SequalPrep™ Normalisation Plate Kit (Invitrogen, Paisley, UK) 
and pooled. Pools were quantified using the Qubit™ dsDNA HS Assay Kit 
(Invitrogen) and diluted to 2 nM. Pools were denatured using sodium hydroxide and 
diluted to 5 pM, and sequenced using the MiSeq v3 600-cycle (2 x 300 bp) reagent 
kit on the Illumina MiSeq platform. 
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2.3 Bioinformatic analysis 
Sequences were processed using Mothur (v1.39.5),37 paired end reads were merged 
using make.contigs with trimoverlap set to true. Any sequence with an ambiguous 
base was removed from the dataset. Reads were assigned taxonomy using the 
UNITE database (v8)38 and only fungal reads were retained for further analysis. A 
rarefied observed taxonomic units (OTU) table was generated for downstream 
analyses of taxa relative abundance, alpha and beta diversity. The total number of 
raw ITS1 reads was 2,497,751 with a median number of reads per sample of 11,039. 
After rarefaction, the number of samples employed in subsequent analyses were 
reduced to 81, with each sample normalised to 1,082 ITS1 sequence reads. A total 
of 90.5% of ITS1 sequences were identified by comparison to the UNITE ITS 
sequence database. The raw sequence data are available from the European 
Nucleotide Archive under the study accession number PRJNA607176. Analyses of 
fungal communities were performed in R (v3.3.1). To evaluate alpha and beta 
diversity of fungal and bacterial communities, the number of observed OTUs, 
Shannon diversity, Jaccard indices and Bray-Curtis dissimilarity values were 
calculated using the “Vegan” package (v 2.5-6).39  
 
2.4 Volatile organic compounds 
The VOC data was generated from a previous study35 using a previously described 
method.40 
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2.5 Statistical analysis 
Statistical analyses were performed using Prism v.8 (GraphPad, San Diego, US), 
Minitab 19 (Minitab Ltd, Coventry, UK) or R (v3.3.1). The distribution of continuous 
variables (age, BMI and faecal calprotectin) were assessed by Anderson-Darling 
normality tests. Proportions of categorical variables were compared using Fisher’s 
exact test. Significance of nonparametric variables was determined using the Mann–
Whitney test for two category comparisons or the Kruskal–Wallis test when 
comparing two or more categories or the Wilcoxon signed rank test for matched pair 
comparisons. Significance of parametric variables was determined using the two-
sample t test for two category comparisons or paired t tests for matched pair 
comparisons. Correlation between continuous variables were assessed using 
nonparametric Spearman rank correlation tests or parametric variables were 
assessed using Pearson’s correlation test. Basidiomycota/Ascomycota ratios were 
calculated for each sample by dividing the percentage relative abundance of 
Basidiomycota with the percentage relative abundance of Ascomycota. Principle 
Coordinate analysis (PCoA) using unweighted Jaccard or weighted Bray-Curtis 
distance was performed to investigate relationships in β-diversity and between 
variable distances were analysed by PERMANOVA. Where applicable P values were 
corrected using the false discovery rate algorithm (FDR).41 To determine the 
associations between the relative abundance of either fungal genera or bacterial 
genera and the intensity of stool VOC, we performed sparse partial least squares 
regression analysis in canonical mode, using MixOmics.42 
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3. RESULTS 
3.1 Characteristics of the study population 
The initial cohort comprised 113 study participants of Caucasian ethnicity 
(Supplementary Table 1), 32 samples were excluded from the study and the 
exclusion criteria are summarised in Figure 1A. Eighty-one participants remained 
and the characteristics of this cohort are summarised in Table 1A. Three household 
control subjects could not be NOD2 genotyped leaving 78 participants for genotype-
stratified analyses (Figure 1B). There were 34 CD patients (53% NOD2 mutant) in 
remission and 47 non-CD individuals (38% NOD2 mutant) without GI disease (22 
household matched volunteers and 25 NIHR Cambridge BioResource volunteers). 
CD patients had lower BMIs and higher faecal calprotectin concentrations. Fifteen 
percent of CD patients were current smokers. A smaller subgroup of 15 CD patients 
(60% NOD2 mutant) were matched with their household control (13% NOD2 
mutant), the characteristics of these groups are summarised in Table 1B. CD 
patients had lower BMIs and higher concentrations of faecal calprotectin. 
 
3.2 Fungal diversity of patients with CD and non-CD individuals 
Using the UNITE ITS database we identified 523 fungal OTUs, which were 
detectable in the stool samples of the cohort and this identified 184 genera.  
Comparing the within sample diversity (alpha-diversity) between CD patients and 
non-CD subjects, we found a significant difference in observed OTUs (Figure 2A; P 
= 0.033) but there was no difference in Shannon diversity (Figure 2A; P = 0.19). We 
examined beta-diversity which considers between sample variation of the fungal 
community using Jaccard indices (considers presence or absence) and Bray-Curtis 
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dissimilarity (considers relative abundance). A significant difference was observed in 
the PCoA using Jaccard indices (Figure 2B; R2 = 0.0184, P = 0.018) and Bray-Curtis 
dissimilarities (Figure 2B; R2 = 0.0246, P = 0.01; PERMANOVA). The genus 
Candida and Cryptococcus appeared most discriminatory where Candida was most 
associated with CD, and Cryptococcus was most associated with non-CD. The 
dominant phyla in the stool mycobiota were Ascomycota and Basidiomycota 
(Supplementary Table S2). Ascomycota were significantly more abundant in CD 
(Figure 2C; FDR-Adj P = 0.001), whereas Basidiomycota were significantly less 
abundant in CD compared to non-CD (Figure 2C; FDR-Adj P = 0.019). We sought to 
determine whether there were significant differences in the relative abundance of 
fungal genera and found no significant difference in genus abundance (Figure 2D). 
The Basidiomycota/Ascomycota abundance ratio was found to be significantly lower 
in CD patients (Figure 2E; P = 0.0051). We investigated whether there were 
correlations in alpha-diversity between the bacterial and fungal communities, but no 
significant correlations in the number of observed OTUs (Figure 2F) or Shannon 
diversity (Figure 2G) by disease status were found.  
 
3.3 CD-specific changes in the mycobiota compared to household matched 
individuals 
We sought to compare the fungal mycobiota composition between CD and non-CD 
shared household contacts. Analysis of the alpha-diversity revealed CD patients had 
a significantly higher number of OTUs (Figure 3A; P = 0.0045, paired t test) and 
Shannon diversity (Figure 3A; P = 0.048, paired t test). PCoA using Jaccard and 
Bray-Curtis indices showed no clustering in the fungal community composition 
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(Figure 3B). There was no significant difference in the relative abundance of any 
fungal phyla or genera between CD and household contacts (Figure 3C and 3D). 
The Basidiomycota/Ascomycota abundance ratio was also not significantly different 
between groups (Figure 3E; P = 0.083, Wilcoxon matched pair test). We 
investigated whether there were correlations in alpha-diversity metrics between 
bacterial and fungal communities in CD and household matched subjects, and found 
no significant correlations in either the number of observed OTUs (Figure 3F) or 
Shannon diversity (Figure 3G).  
3.4 Faecal mycobiota-NOD2 genotype association 
To examine the impact of NOD2 genotype on the stool mycobiota we compared the 
relative abundance of fungal phyla and genera between 42 NOD2 wild-type vs. 36 
NOD2 mutant subjects (19 compound heterozygotes, 3 frameshift homozygotes, 10 
other homozygotes and 4 single heterozygotes). These analyses were independent 
of Crohn’s disease. Comparing alpha-diversity, we found no significant differences in 
observed OTUs (Figure 4A; FDR Adj. P = 0.43) or Shannon diversity (Figure 4A; 
FDR Adj. P = 0.57). The fungal profiles were comparable between NOD2 wild-type 
and NOD2 mutant subjects using Jaccard indices (Figure 4B; R2 = 0.0131, P = 
0.494) and Bray-Curtis (Figure 4B; R2 = 0.0141, P = 0.321). There were no 
significant differences in the relative abundance of Ascomycota (Figure 4C; FDR 
Adj. P = 0.28) or Basidiomycota (Figure 4C; FDR Adj. P = 0.23) or genera (Figure 
4D).The Basidiomycota/Ascomycota abundance ratio was not found to be 
significantly different (Figure 4E; P = 0.182, Mann-Whitney test). We investigated 
whether there were correlations in alpha-diversity between bacterial and fungal 
communities and found no significant correlations in either observed OTUs (Figure 
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4F) in either wild-type NOD2 (r = -0.072; P = 0.662) or mutant NOD2 (r = -0.060; P = 
0.729). However, there was a significant correlation between the bacterial and fungal 
Shannon diversity (Figure 4G) in wild-type NOD2 individuals (r = -0.349; P = 0.029) 
but this was not significant in NOD2 mutant subjects (r = -0.238; P = 0.162).  
3.5 The impact of NOD2 mutations on the alpha-diversity of the mycobiota in 
Crohn’s disease 
We sought to determine whether NOD2 was associated with the stool mycobiota in 
34 CD patients (16 NOD2 wild-type vs. 18 NOD2 mutant) and 44 non-CD individuals 
(26 NOD2 wild-type vs. 18 NOD2 mutant). Three samples could not be conclusively 
genotyped so were excluded from this analysis (supplementary Figure S1A). There 
were no significant differences between CD patients with NOD2 wild-type and NOD2 
mutant in either observed OTUs (FDR Adj. P = 0.685) or Shannon diversity (FDR 
Adj. P = 0.85). In non-CD individuals, we found no significant differences between 
NOD2 wild-type and NOD2 mutant subjects in either observed OTUs (FDR Adj. P = 
0.435) or Shannon diversity (FDR Adj. P = 0.63). Four non-CD subjects carried a 
heterozygous NOD2 mutation. Excluding these samples and repeating the analysis, 
we found no significant differences between 26 NOD2 wild-type and 14 mutant 
subjects in either observed OTUs (FDR Adj. P = 0.42) or Shannon diversity (FDR 
Adj. P = 0.80).  
Finally, we sought to determine whether NOD2 would exert the strongest effect on 
the alpha-diversity of the stool mycobiota in CD patients and non-CD subjects 
matched for age, gender and geography. We compared 9 CD NOD2 wild-type 
subjects vs. 9 CD NOD2 mutant subjects and found no significant differences in 
observed OTUs (supplementary Figure S1B; P = 0.436, paired t test) or Shannon 
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diversity (supplementary Figure S1B; P >0.999, Wilcoxon test). In non-CD 
individuals we compared 10 NOD2 wild-type vs. 10 NOD2 mutant subjects and 
found no significant differences in observed OTUs (supplementary Figure S1C; P = 
0.677, paired t test) or Shannon diversity (supplementary Figure S1C; P = 0.544, 
paired t test). 
 3.6 Fungal and bacterial interactions 
To determine whether there were correlations in the relative abundance of fungal 
and bacterial genera, we performed sparse partial least squared (sPLS) regression. 
We identified pairwise positive correlations in the faecal mycobiota in samples 
between genera Wallemia and Anaerostipes, Debaryomyces and Pseudobutyrivibrio, 
Cryptococcus and Ruminococcus, Saccharomyces and Escherichia/Shigella, and 
Sordariomyces and Clostridium-sensu-stricto-1 (Figure 5A).  Previous work on these 
samples profiled the VOC in the faecal contents of the CD patients and non-CD 
subjects and found the concentration of pentanoic acid, 2-butanone, acetone and 2-
hexanone, 5-methyl were significantly lower in CD and the concentration of 2-
piperidinone and butanoic acid, 3-methyl-, ethyl ester were significantly higher in 
CD.35 We sought to look at the relationship of these CD-discriminating VOCs with the 
relative abundance of fungal genera employing a canonical correlation analysis 
approach (Figure 5B) and identified a strong positive correlation between CD-
associated Candida spp. and the CD-associated VOC 2-piperidinone, and 
Debaryomyces with the CD-associated VOC 2-hexanone, 5-methyl-.  
We also sought to determine the relationship of the VOCs with the bacterial genera 
(Figure 5C) and identified strong inverse relationships between Prevotella with 2-
piperidinone, the bacterial genera Dorea, Blautia and Alistipes showed a negative 
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correlation with acetone and 2-butanone. The genus Faecalibacterium was 
negatively associated with pentanoic acid and 2-hexanone, 5-methyl- and 
Pseudobutyrivibrio inversely correlated with the concentration of pentanoic acid.   
4. DISCUSSION 
This study reports that CD patients in clinical remission have higher fungal diversity 
compared to a non-inflammatory, non-CD comparator group. We found significantly 
higher observed OTUs in CD and the fungal profiles of CD patients clustered 
distinctly from that of non-CD subjects, with Candida spp. and Cryptococcus spp. 
found to cluster with CD and non-CD subjects, respectively. We identified shifts in 
the fungal phyla composition in CD patients, notably lower Basidiomycota that 
include Cryptococcus spp. and higher Ascomycota that include Candida spp. 
However, following correction for multiple comparisons, there were no significant 
differences found in the relative abundance of fungal genera in CD patients and non-
CD individuals. We also report significantly higher alpha-diversity in CD patients 
compared to their respective household matched control. A strength of this study 
was that it included well-characterised CD and non-CD participants of known NOD2 
genotype. We compared the faecal mycobiota of subjects stratified by NOD2 
genotype and in the presence or absence of CD and found no differences were 
evident.  
We found CD-specific shifts in the abundance of Ascomycota and Basidiomycota. 
The Basidiomycota/Ascomycota ratio in non-CD subjects was approximately 1:2, 
and this increased to 1:8 in CD patients. Ascomycota dominated the fungal 
community in CD patients and this finding was independent of intestinal 
inflammation. Our findings confirm previously identified shifts in fungal phyla in the 
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stool mycobiota of CD patients compared to non-CD controls.17-19,43 The study by 
Sokol and colleagues reported that during intestinal inflammatory flare the 
abundance of Basidiomycota increased markedly, whilst the abundance of 
Ascomycota decreased, and that the Basidiomycota/Ascomycota ratio increased 
with increasing inflammation.17 In contrast, our study excluded any participants with 
evidence of disease activity and found that Ascomycota was the dominant phyla in 
CD patients and the Basidiomycota/Ascomycota ratio were decreased.   
A number of faecal mycobiota studies in CD patients have found an association with 
Candida albicans, although the functional importance of this association remains 
unknown.17,19,43 Our data found that C. albicans was the most abundant species in 
CD patients and also in individuals with CD-associated NOD2 mutations. A study by 
Hoarau and colleagues found that Candida Tropicalis was significantly higher in CD 
patients and correlated positively with serum ASCA.18 In our study, C. tropicalis was 
the 8th most abundant species identified in CD patients, however, there were no 
significant differences found between CD and non-CD subjects. It was also 
interesting to note that one CD patient was detectable for nearly 80% of all C. 
Tropicalis ITS1 reads and this patient had CD-associated NOD2 mutations.  
Recently Limon and co-authors found that Malassezia restricta was more abundant 
in CD patients with the single-nucleotide polymorphism CARD9S12N, which normally 
expresses a key signalling adaptor that plays an important role in anti-fungal 
immunity.44 Curiously, we did not detect M. restricta in our cohort. This discrepancy 
is potentially due to sampling differences. We used stool samples, whereas Limon 
and colleagues used intestinal wash samples, which have different microbial 
communities than stool.45 The observation may also relate to demographic 
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differences of the respective cohorts; all our study participants were recruited from 4 
locations in the UK, whereas the subjects in the Limon study were recruited from 
California, US.   
Our study found that fungal diversity is higher in CD and this was independent of 
inflammation. This contrasts with the well-established lower bacterial diversity seen 
in CD, 11-13,35 and may indicate fungi fill this niche in CD. The inclusion of matched 
VOC data from a previous study35 enabled us to look at associations between 
metabolites and relative bacterial and fungal abundance. One of the primary routes 
with which the gut microbiota may interact and cross-communicate with each other, 
and the host is through the production of volatile metabolites. Previous studies report 
that the faecal concentration of the ketone 2-piperidinone is higher in CD during 
active disease and remission. 35,46 The present study sought to evaluate correlations 
between fungal and bacterial communities with faecal VOC, and identified a positive 
correlation between  Candida spp. and 2-piperidinone, and a negative correlation 
between 2-piperidinone and Prevotella spp., which is intriguing. Future studies to 
assess if this compound has anti-bacterial properties that confer a competitive 
advantage to yeast and enables Candida spp. to outcompete commensal bacteria 
such as Prevotella would be helpful to interrogate the functional relationship of these 
microbes and VOC.  
A study by Wagener and colleagues found that there were chitin-dependent 
pathways of NOD2 activation that lead to interleukin-10 secretion and promote 
intestinal homeostasis36 leading to the hypothesis that the mycobiota of CD patients 
with NOD2 mutations would differ to wild-type individuals. Our findings suggest that 
there is no difference in the faecal mycobiota between NOD2 wild-type or mutant 
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individuals with or without CD. However, CD patients with NOD2 mutations often 
have ileal involvement and a more aggressive fistulising and fibrostenotic disease 
phenotype, and increased risk of postsurgical disease recurrence post-ileal 
resection.47-49 Evidence from animal models50 and human studies 45 show there is a 
modest correlation between the microbial contents of the stool and ileal wash 
samples, which suggests future studies are warranted that should include paired 
samples to determine the impact of NOD2 genotype on the ileal-associated 
microbiome. 
The present study has a number of strengths. The study included a cohort of well-
characterised CD patients and non-CD subjects with known NOD2 genotypes. 
Importantly, the study excluded participants with raised faecal calprotectin levels, 
thereby reducing the confounding influence of inflammation, which is a key stressor 
to the gut mycobiota.17 The study design enabled comparisons between CD vs. non-
CD controls, CD NOD2 wild type vs. CD NOD2 mutant, non-CD NOD2 wild type vs. 
non-CD NOD2 mutant, and CD vs. matched household. The latter grouping was 
important as unaffected individuals sharing the same household environment with a 
CD patient may also show signs of bacterial dysbiosis.51 Our findings show that the 
fungal community of CD patients are richer and more diverse than the mycobiota of 
their respective household controls.  
Some study limitations should be noted. Reflective of the complexity of undertaking a 
genotype-stratified study, despite recruitment from the UK IBD Genetics cohort via 
several IBD centres, the absolute number of participants and the number of 
participants in each group (CD patients, non-CD subjects, matched household 
subjects, wild-type NOD2 and mutant NOD2), and samples in this multi-omic 
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analysis is relatively small. Furthermore, this study evaluated the impact of the most 
common NOD2 genetic variants on the mycobiota and stratified participants into two 
groups (wild-type NOD2 and mutant NOD2) as we recognised it was underpowered 
to examine the effects of individual genotypes including the effect of rarer NOD2 
variants.52 To remove the confounding influence of inflammation, our study recruited 
CD patients in remission. However, it is possible that the greatest impact of NOD2 
genotype on the gut mycobiota will manifest during active disease. We also did not 
undertake functional analysis regarding NOD2 activity in the respective CD-
associated NOD2 mutations, and thus did not determine whether there was aberrant 
fungal sensing or handling in NOD2 mutant subjects compared to NOD2 wild-type. 
Finally, this study characterised fungal taxonomy by employing an ITS1 amplicon 
DNA sequencing approach and recognise that there may be variation in the 
taxonomic resolution of the fungal communities by targeting alternative genetic 
markers such as ITS2, 18S and 28S rRNA. 53 
In conclusion, this study shows that fungal diversity is higher and bacterial diversity 
is lower in CD. We show CD-specific changes in fungal diversity, which importantly is 
independent of inflammatory flare. Using stool samples, we could not identify specific 
associations of NOD2 genotype with the mycobiota in CD patients or non-CD 
subjects. Candida spp. clustered more closely with CD and highlights the need for 
further studies to characterise whether Candida is a gut commensal or a pathogen in 
CD patients. Future investigations should also explore the impact of NOD2 genotype 
on the ileal-associated mycobiota in larger cohorts stratified by NOD2 genotype to 
resolve these complex mucosal interactions. 
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TABLE 1. Overview of the clinical characteristics of the study cohort 
A. Crohn's disease patients and non-Crohn's disease individuals (n = 81) 
Characteristic 
Crohn's disease  
(n = 34) 
Non-Crohn's disease  
(n = 47) 
P 
Gender (Fn,%) 21 (62%) 22 (47%) 0.259 
Age (yrs), median (Q1-Q3) 53 (44 - 64) 57 (45 - 64) 0.77 
BMI (kg/m2), median (Q1-Q3) 23.4 (21.4 - 27.0) 25.7 (23.0 - 29.1) 0.007 
Ethnicity   
ND 
White - British 32 45 
White - Irish 1 0 
White - Other 1 2 
Faecal calprotectin (µg/g), median (Q1-Q3) 50 (19 - 115) 19 (19 - 30) <0.001 
Current smoker, n (%) 5 (15%) 0 (0%) 0.011 
NOD2 genotype; n (%)   
ND 
Wild-type 16 (47%) 26 (55%) 
Compound heterozygote 11 (32%) 8 (17%) 
Frameshift homozygote 3 (9%) 0 (0%) 
Other homozygote 4 (12%) 6 (13%) 
Heterozygote 0 (0%) 4 (9%) 
Not determined 0 (0%) 3 (6%) 
Antibiotics in last 12 months; n (%) 16 (47%) 12 (26%) 0.059 
Medication; n (%)   
ND 
NSAID/aspirin 6 (18%) 9 (19%) 
5ASA 10 (29%) 0 (0%) 
Systemic steroids 1 (3%) 0 (0%) 
Immunomodulator 12 (35%) 0 (0%) 
Anti-TNF 2 (6%) 0 (0%) 
Bile acid sequestrants 9 (26%) 0 (0%) 
Proton pump inhibitors 9 (26%) 3 (6%) 
Probiotics; n (%) 3 (9%) 3 (6%) 0.692 
B. Crohn's disease subgroup with household matched individuals (n = 30) 
Characteristic 
Crohn's disease  
(n = 15) 
Household matched 
individuals (n = 15) 
 
Gender (Fn,%) 9 (60%) 6 (40%) 0.466 
Age (yrs), median (Q1-Q3) 44 (38 - 64) 45 (40 - 65) 0.793 
BMI (kg/m2), median (Q1-Q3) 21.9 (21.1 - 22.9) 26.2 (22.8 - 28.5) 0.005 
Faecal calprotectin (µg/g), median (Q1-Q3) 50 (19 - 170) 19 (19 - 30) 0.024 
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Current smoker, n (%) 2 (13%) 0 (0%) 0.483 
Antibiotics in last 12 months, n (%) 7 (47%) 5 (33%) 0.71 
Probiotics, n (%) 2 (13%) 0 (0%) 0.483 
NOD2 genotype; n (%)   
ND 
Wild-type 6 (40%) 10 (67%) 
Compound heterozygote 3 (20%) 0 (0%) 
Frameshift homozygote 2 (13%) 0 (0%) 
Other homozygote 4 (27%) 0 (0%) 
Heterozygote 0 (0%) 2 (13%) 
Not determined 0 (0%) 3 (20%) 
Non-CD, Non-Crohn’s disease; BMI, Body Mass Index; NOD2, Nucleotide-binding oligomerisation domain-containing protein 2; 
ND, Not Determined. 5-ASA, 5-amino salicylates; TNF, tumour necrosis factor. 
Medications: 5-amino salicylates: mesalazine/sulfasalazine, Systemic steroids: prednisolone, Immunomodulators: 
Azathioprine/methotrexate, Anti-TNF: Adalimumab, Proton-pump inhibitor: 
Esomeprazole/Omeprazole/Lansoprazole/Rabiprazole, Bile acid sequestrants: Colestyramine/Colesevelam 
All data variable were non-parametric and were summarised as the median value (Q1-Q3). Proportional categorical variables 
were compared using a 2 x 2 contingency table Fisher’s exact test. The medians of CD and non-CD subjects were compared 
using the Kruskal-Wallis test. P <0.05 were considered significant. 
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FIGURE LEGENDS 
FIGURE 1. Flow diagrams summarising study participants inclusion criteria 
and NOD2 analyses. A.) Data from 34 CD patients and 47 non-CD individuals were 
used in the primary analysis B.) Flow of NOD2 analyses to evaluate the impact of 
NOD2 mutations on the mycobiota independently of disease and to look at disease-
NOD2 specific alterations. 
 
FIGURE 2. Altered mycobiota diversity in CD patients during remission 
compared to non-CD individuals. A.) Observed number of OTU and Shannon 
diversity of the mycobiota. The centre line denotes the median, the boxes cover the 
interquartile range (Q1-Q3), and the whiskers extend to the most extreme data point, 
which is no more than 1.5 times the length of the box away from the box. Points 
outside the whiskers represent outlier samples. (The ranges and descriptive 
statistics are the same for panel C and D) B.) Beta diversity metrics (Jaccard Index 
and Bray-Curtis dissimilarity C.) Percentage relative abundance of Ascomycota and 
Basidiomycota. D.) Percentage relative abundance of the top 10 most abundant 
fungal genera E.) Basidiomycota/Ascomycota ratio. The middle lines are the median 
ratio, the boxes cover the interquartile ranges (Q1-Q3). The whiskers show the range 
from the minimum ratio to the maximum ratio F.) Association between bacterial and 
fungal observed OTUs in CD and non-CD (Spearman’s rank correlation test applied 
to both groups) and G.) Association between bacterial and fungal Shannon diversity 
metrics in CD (Pearson’s correlation) and non-CD (Spearman’s rank correlation). 
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Where relevant P values were adjusted for multiple comparisons using FDR and 
considered significant if P < 0.05. 
FIGURE 3. Altered mycobiota diversity in CD patients during remission 
compared to household matched controls. A.) Alpha-diversity metrics (observed 
OTUs and Shannon). The centre line denotes the median, the boxes cover the 
interquartile range (Q1-Q3), and the whiskers extend to the most extreme data point, 
which is no more than 1.5 times the length of the box away from the box. Points 
outside the whiskers represent outlier samples. (The ranges and descriptive 
statistics are the same for panel C and D) B.) Beta-diversity metrics (Jaccard Index 
(presence/absence of fungal genera) and Bray-Curtis distance (relative abundance 
of fungal genera)) C.) Relative abundance of Ascomycota and Basidiomycota. D.) 
Percentage relative abundance of the top 10 most dominant fungal genera E.) 
Basidiomycota/Ascomycota ratio. The middle lines are the median ratio, the boxes 
cover the interquartile ranges (Q1-Q3). The whiskers show the range from the 
minimum ratio to the maximum ratio F.) Association between bacterial and fungal 
observed OTUs in CD and non-CD (Spearman’s rank correlation test applied to both 
groups) and G.) Association between bacterial and fungal Shannon diversity metrics 
in CD (Pearson’s correlation) and non-CD (Spearman’s rank correlation). Where 
relevant P values were adjusted for multiple comparisons using FDR and considered 
significant if P < 0.05. 
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FIGURE 4. Evaluating the impact of NOD2 genotype independently of CD. A.) 
Alpha-diversity metrics (observed OTUs and Shannon) B.) Beta-diversity metrics 
(Jaccard Index (presence/absence of fungal genera) and Bray-Curtis distance 
(relative abundance of fungal genera)) C.) Relative abundance of Ascomycota and 
Basidiomycota. The centre line denotes the median, the boxes cover the interquartile 
range (Q1-Q3), and the whiskers extend to the most extreme data point, which is no 
more than 1.5 times the length of the box away from the box. Points outside the 
whiskers represent outlier samples. (The ranges and descriptive statistics are the 
same for panel C and D) D.) Percentage relative abundance of the top 10 most 
prevalent fungal genera E.) Basidiomycota/Ascomycota ratio. The middle lines are 
the median ratio, the boxes cover the interquartile ranges (Q1-Q3). The whiskers 
show the range from the minimum ratio to the maximum ratio F.) Association 
between bacterial and fungal observed OTUs in NOD2 wild-type and NOD2 mutant 
subjects (Spearman’s rank correlation test applied to both groups) and G.) 
Association between bacterial and fungal Shannon diversity metrics in NOD2 wild-
type subjects (Pearson’s correlation) and NOD2 mutant subjects (Spearman’s rank 
correlation). Where relevant P values were adjusted for multiple comparisons using 
FDR and considered significant if P < 0.05.  
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FIGURE 5. Canonical correlation analyses showing fungal and bacterial  
interactions and that certain volatile organic compounds (VOCs) associate 
strongly with the relative abundance of fungal and bacterial communities. 
These analyses are not stratified by disease or NOD2 genotype and include n = 81 
study participants. The red and blue shading indicate the strength of the positive and 
negative associations, and yellow shading indicates weak to no association. A.) 
Shows the association between the 5 most dominant fungal genera with 5 most 
dominant bacterial genera. B.) Shows the association between 8 fungal genera and 
the 6 most discriminative VOCs (CD vs. non-CD). C.) Shows the association 
between 10 bacterial genera and the 6 most discriminative VOCs (CD vs. non-CD). 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
 
D
ow
nloaded from
 https://academ
ic.oup.com
/ecco-jcc/advance-article/doi/10.1093/ecco-jcc/jjaa220/5942946 by guest on 05 D
ecem
ber 2020
